Mesoblast, a global leader in allogeneic cellular medicines, announced its financial results for the fiscal year ended June 30, 2024, highlighting significant progress in its clinical development programs and a focus on cost containment. The company’s key product candidates, RYONCIL (remestemcel-L) and REVASCOR (rexlemestrocel-L), are showing promise in treating various inflammatory and heart conditions.